Europe Biguanide Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Overview

Europe Biguanide Market Snapshot & Metrics Overview

Study Period	2021 - 2032
Forecast Data Period	2027 - 2032
Base Year Market Size (2026)	USD 1.29 Billion
Market Size (2027)	USD 1.30 Billion
Market Size (2032)	USD 1.38 Billion
Growth Rate (2027 - 2032)	1.27 %
Market Concentration	Medium
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

• Asia
• Middle East and Africa
• North America
• South America

Market Trends and Insights

Increasing diabetes prevalence

The diabetes population in the European region is expected to rise by more than 5% over the forecast period.

Metformin continues to maintain a dominant position in the treatment algorithm for type 2 diabetes across Europe, supported by recommendations from regional and national clinical guidelines as the preferred first-line pharmacological therapy. For instance, the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) consensus reports continue to recommend metformin as the foundational therapy for many patients with type 2 diabetes, either as monotherapy or in combination with newer agents. Despite the growing adoption of GLP-1 receptor agonists and SGLT-2 inhibitors, metformin's established efficacy, extensive clinical experience, and low treatment cost continue to support high prescription volumes, reinforcing demand within the European biguanide market.

Oral anti-diabetic drugs have been available internationally and are recommended for use when escalation of treatment for type-2 diabetes is required along with lifestyle management. These are typically the first medications used in the treatment of type-2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Antidiabetic drugs help diabetes patients keep their condition under control and lower the risk of diabetes complications. People with diabetes may need to take antidiabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. They present the advantages of easier management and lower cost, so they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

The government, along with the companies, are working towards better diabetes management. For instance, the National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind.

Owing to the rising rate of obesity, the growing genetic factors for type-2 diabetes, the increasing prevalence, and the aforementioned factors, it is likely that the market will continue to grow.

Germany holds the highest market share in the Europe Biguanide Market in the current year

Germany has one of Europe's most established Disease Management Programs (DMPs) for diabetes, which promotes structured monitoring and long-term management of patients with type 2 diabetes. The widespread adoption of these programs has increased treatment adherence and early therapeutic intervention, supporting continued utilization of biguanide-based therapies within routine clinical practice.

The Europe biguanide market continues to benefit from the widespread inclusion of biguanide therapies in national reimbursement programs and public healthcare formularies. Across major European countries, healthcare authorities emphasize cost-effective diabetes management strategies to address the growing economic burden of chronic disease. As a result, biguanides remain an important component of glucose-lowering treatment regimens, supporting consistent utilization across the region.

About 8.5 million people in Germany suffer from diabetes, according to the German Diabetes Center (DDZ). The number of people with type-2 diabetes in Germany will continue to increase over the next twenty years. German law requires public plans to cap out-of-pocket health care costs and to cover all medically necessary treatment, including insulin. Germany is one of the most developed countries in terms of healthcare facilities. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market. The roll-out of many new products, increasing international research collaborations in technological advancement, and increasing awareness about diabetes among people are some of the market opportunities for the players in the German diabetes drug market.